within Pharmacolibrary.Drugs.ATC.C;

model C02CA01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.000225,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.307,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008833333333333334,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.158,
    k12             = 76.3,
    k21             = 76.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C02CA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Prazosin is an alpha-1 adrenergic receptor antagonist primarily used for the treatment of hypertension and symptoms of benign prostatic hyperplasia. It is also used off-label in the management of post-traumatic stress disorder (PTSD)-associated nightmares in adults. Prazosin is an approved and commonly used medication today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult male subjects after oral administration.</p><h4>References</h4><ol><li><p>Jaillon, P (1980). Clinical pharmacokinetics of prazosin. <i>Clinical pharmacokinetics</i> 5(4) 365–376. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198005040-00004&quot;>10.2165/00003088-198005040-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6994981/&quot;>https://pubmed.ncbi.nlm.nih.gov/6994981</a></p></li><li><p>Dynon, MK, et al., &amp; Louis, WJ (1980). Pharmacokinetics of prazosin in normotensive subjects after low oral doses. <i>Clinical pharmacokinetics</i> 5(6) 583–590. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198005060-00007&quot;>10.2165/00003088-198005060-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7438656/&quot;>https://pubmed.ncbi.nlm.nih.gov/7438656</a></p></li><li><p>Bateman, DN, et al., &amp; Rawlins, MD (1979). Prazosin, pharmacokinetics and concentration effect. <i>European journal of clinical pharmacology</i> 16(3) 177–181. DOI:<a href=&quot;https://doi.org/10.1007/BF00562058&quot;>10.1007/BF00562058</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/499317/&quot;>https://pubmed.ncbi.nlm.nih.gov/499317</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C02CA01;
